Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR1 | Q92633 | 4/20 | 0.61 |
| ▸ | GRIK1 | P39086 | 1/20 | 0.52 |
| ▸ | PYGL | P06737 | 3/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 7/20 | 0.51 |
| ▸ | MEN1 | O00255 | 6/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27754464 | 0.84 | LPAR1 (0.60) | LPAR1GRIK1PYGLKMT2AMEN1 | |
| SCHEMBL13695133 | 0.82 | PKM (0.59) | LPAR1GRIK1PYGLKMT2AMEN1 | |
| SCHEMBL1853287 | 0.82 | LPAR1 (0.58) | LPAR1GRIK1PYGLKMT2AMEN1 | |
| SCHEMBL4852258 | 0.82 | KDM4E (0.58) | LPAR1PYGLKMT2AMEN1ALDH1A1 | |
| SCHEMBL19643985 | 0.81 | LPAR1 (0.60) | LPAR1KMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL13556615 | 0.80 | MAPT (0.60) | LPAR1GRIK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL1504060 | 0.79 | LPAR1 (0.56) | LPAR1GRIK1PYGLKMT2AMEN1 | |
| SCHEMBL9035650 | 0.78 | RAB9A (0.58) | PYGLKMT2AMEN1ALDH1A1KDM4E | |
| SCHEMBL6993599 | 0.78 | KMT2A (0.55) | LPAR1GRIK1KMT2AMEN1ALDH1A1 | |
| SCHEMBL11816896 | 0.78 | TRPV4 (0.46) | LPAR1KMT2AMEN1ALDH1A1KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6887863-B2 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES (US) | 2005-05-03 | — | — | US | disclosed |
| EP-1272456-B1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LAB (US) | 2004-10-27 | — | — | EP | disclosed |
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBVIE INC. | 2004-08-26 | — | — | US | disclosed |
| EP-1272456-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | Abbott Laboratories (US) | 2003-01-08 | — | — | EP | disclosed |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | ABBOTT LABORATORIES | 2002-01-03 | — | — | US | disclosed |
| WO-2001079157-A1 | HYDRAZIDE AND ALKOXYAMIDE ANGIOGENESIS INHIBITORS | ABBOTT LABORATORIES (US) | 2001-10-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040167126-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | LPAR1 2733/4885GRIK1 3589/4885PYGL 2268/4885 |
| US-20020002152-A1 | Hydrazide and alkoxyamide angiogenesis inhibitors | METAP2, METAP1, ANPEP | LPAR1 2733/4885GRIK1 3589/4885PYGL 2268/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.